Search results for: Value-Based Pricing
Filter search results
Groundbreaking EQ-5D Project Launched in the United Arab Emirates
5 November 2013
…a new programme to measure and value health in the United Arab Emirates (UAE). Workshop launches new EQ-5D project in the UAE OHE’s Professor Nancy Devlin and Koonal Shah…
OHE’s Adrian Towse to Take Office as ISPOR President
3 June 2014
…conference of 2014, in Amsterdam in November. ISPOR’s publications are global and now include not only our flagship journal Value in Health, but also three regional issues of Value in Health —…
What is the Normative Basis for Selecting the Measure of ‘Average’ Preferences for Use in Social Choices?
1 February 2017
…values. We begin by providing examples of the importance and implications of the… The aim of this paper is to consider what normative arguments might exist for advocating the use…
Prevention pays off – so why aren’t we doing more of it?
5 June 2025
…on child immunisation delivery, but seem to be overlooking the value of adult immunisations. In the UK for example, the adult immunisation framework is limited to only 5 out of 18 possible…
New ISPOR Task Force Report on Multiple Criteria Decision Analysis
9 February 2016
Professor Nancy Devlin co-chaired the ISPOR task force on uses of MCDA in health care decision making. The first report from the task force has just been published in Value…
Can the US Afford to Ignore Cost-effectiveness Evidence?
1 March 2014
Cost-effectiveness analysis plays a limited role in US health care compared to many other countries. In this Seminar Briefing, Dr James Chambers, Center for the Evaluation of Value and Risk…
Accounting for Preference Heterogeneity in Discrete Choice Experiments
4 May 2022
…people with experience of infertility value different aspects of Assistive Reproductive Therapy (Skedgel et al., 2021). Another OHE-led study compared the preferences of adults and adolescents for different EQ-5D-Y health…
Are Recommendations for HTA of Gene Therapies Being Achieved?
11 September 2023
…at capturing the full value of gene therapies should lead to more timely access. Several countries are achieving some of the changes recommended in a previous OHE report, demonstrating examples…
OHE is pleased to appoint two Senior Visiting Fellows: Professor David Parkin and Professor Lou Garrison
5 October 2016
…Evidence Generation Risk-Sharing Agreements Between Pharmaceutical Manufacturers and Payers Personalised Medicine and the Value of Molecular Diagnostics Governance models for real-world evidence The Expanding Value Footprint of Oncology Treatments Lou…